Evidence map›Paper›PMID 35128157›Full record

ArticleAmerican journal of ophthalmology case reports2022

Topical treatment of dupilumab-associated refractory conjunctivitis and keratitis.

Federico Di Staso, Alessandro Lambiase, Silvio Di Staso, Irene Gattazzo, Marco Ciancaglini, Gianluca Scuderi

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Federico Di StasoOphthalmology Unit, Neurosciences, Mental Health and Sensory Organs Department, St. Andrea Hospital, Sapienza University of Rome, 00100, Rome, Italy.
Alessandro LambiaseDepartment of Sense Organs, Policlinico Umberto I, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185, Rome, Italy.
Silvio Di StasoOphthalmic Clinic, Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100, L'Aquila, Italy.
Irene GattazzoOphthalmology Unit, Neurosciences, Mental Health and Sensory Organs Department, St. Andrea Hospital, Sapienza University of Rome, 00100, Rome, Italy.
Marco CiancagliniOphthalmic Clinic, Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100, L'Aquila, Italy.
Gianluca ScuderiOphthalmology Unit, Neurosciences, Mental Health and Sensory Organs Department, St. Andrea Hospital, Sapienza University of Rome, 00100, Rome, Italy.
Sapienza University of Rome · ITUniversity of L'Aquila · ITPoliclinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo report 3 cases of severe dupilumab-related conjunctivitis and keratitis topical treatment. OBSERVATION: Description, management, and outcomes of dupilumab-related refractory conjunctivitis associated with punctate keratitis.Three patients with atopic dermatitis (AD) experiencing severe ophthalmic complications following dupilumab treatment were referred to us when conventional management methods failed. We treated them topical and external pimecrolimus 10 mg/g cream to the eyelids. The patients showed substantial clinical remission within 10 days. CONCLUSIONS AND IMPORTANCE: Those cases are remarkable as a drug applied externally to the eyelid skin successfully treated underlying conjunctivitis and punctate keratitis. The complete clinical remission suggests that pimecrolimus applied topically to the eyelid skin is a safe and effective delivery route. The resolution of the keratitis and conjunctivitis presumably represents either a contiguous effect of the improvement of the cutaneous inflammation, or the effect of transcutaneous pimecrolimus penetration through the eyelid.Further studies are needed to support the use of this drug for dupilumab-associated conjunctivitis.

Indexed as

Atopic dermatitisConjunctivitisDupilumabKeratitis

Identifiers

PMID35128157
PMCPMC8807984
OpenAlexW4206907811

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.